Checked.be
Active
BE 0478.931.263Private limited company
ENDOCRINE UNIT
Zwartkeeltjeslaan 169 ·1160 Oudergem, Belgium· 23 yrs active
Sector: Specialist medical practice
(86220)
Conclusion
ENDOCRINE UNIT has been active since 2002 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €680k and a net result of €75k. Equity is growing by ~7.2% per year across the filed fiscal years. Its solvency ranks better than 69% of 98 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Based on the State Gazette, CBE and 3 annual accounts.
Key figures
| Equity | €680k |
| Net result | €75k |
| Better than sector | 69% |
| Active | 23 yrs |
Financial profile
79
/ 100
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Health
90
Profitability
55
Solvency
100
Growth
52
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
Long-established
Founded in 2002, 23 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
90
/ 100
Excellent
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€60k
estimate, not credit advice
Score history
93
2023
100
2024
90
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 5.49 (≥ 1.5)
+10
Quick ratio
Quick ratio 5.49 (≥ 1.0)
+5
Leverage
Debt/equity 0.31 (< 1.0)
+10
Profitability
ROE 11% (≥ 10%)
+10
Interest coverage
Interest coverage 69.4× (≥ 3×)
+8
Profit trend
Net profit down YoY
-3
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 15-10-2025 with the NBB · fiscal year 2025 · full schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Equity: growth of ~7.2%/year over 3 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 86, Human health activities · compared within the same schema type (full schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 66.2% | 43.6% | |
| Net result | €75k | €49k | |
| Equity | €680k | €111k | |
| Gross operating margin | €309k | €159k | |
| Total assets | €1.03M | €415k |
€170k
-52.1%
23-25
€75k
-71.7%
23-25
€94k
-69.1%
23-25
€1.03M
+17.7%
23-25
€680k
-7.6%
23-25
€647k
+19.8%
23-25
€77k
+18.4%
23-25
€132k
+17.4%
23-25
€211k
+55.3%
23-25
€144k
+161.8%
23-25
€67k
-17.2%
23-25
5.49
-49.2%
23-25
5.49
-49.2%
23-25
66.2%
-21.5%
23-25
0.31
+68.1%
23-25
11.1%
-69.4%
23-25
7.3%
-76.0%
23-25
69.42
-41.0%
23-25
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Deposit | full schema | full schema | full schema |
| Revenue | - | - | - |
| EBITDA | €170k | €355k | €223k |
| Net profit | €75k | €267k | €174k |
| Cash flow | €94k | €305k | €196k |
| Staff costs | - | - | - |
| Income taxes | €77k | €65k | €37k |
| Dividends | €132k | €112k | €79k |
| Total assets | €1.03M | €872k | €794k |
| Equity | €680k | €736k | €582k |
| Debt | €211k | €136k | €212k |
| of which ≤ 1y | €144k | €55k | €117k |
| of which > 1y | €67k | €81k | €95k |
| Working capital | €647k | €540k | €408k |
| Employees (FTE) | - | - | - |
Ratios (computed)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Current ratio | 5.49 | 10.83 | 4.48 |
| Quick ratio | 5.49 | 10.83 | 4.48 |
| Working capital ratio | 63.0% | 62.0% | 51.4% |
| Solvency | 66.2% | 84.4% | 73.3% |
| Debt / equity | 0.31 | 0.18 | 0.36 |
| Long-term debt ratio | 0.10 | 0.11 | 0.16 |
| Interest coverage | 69.42 | 117.61 | 93.05 |
| Gross margin | - | - | - |
| Net margin | - | - | - |
| ROA | 7.3% | 30.6% | 22.0% |
| ROE | 11.1% | 36.2% | 30.0% |
| EBITDA margin | - | - | - |
| Days sales outstanding | - | - | - |
| Days payable outstanding | - | - | - |
| Inventory turnover | - | - | - |
| Days inventory (DSI) | - | - | - |
Balance-sheet composition 2025
Full annual accounts (26 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Balance sheet, Assets | ||||
| TOTAL ASSETS | 20/58 | €1.03M | €872k | €794k |
| Fixed assets | 21/28 | €236k | €277k | €269k |
| Tangible fixed assets | 22/27 | €236k | €277k | €266k |
| Financial fixed assets | 28 | €250 | €250 | €3k |
| Current assets | 29/58 | €791k | €595k | €525k |
| Amounts receivable within one year | 40/41 | - | €22k | €120k |
| Investments | 50/53 | €326k | €253k | €227k |
| Cash & bank | 54/58 | €460k | €317k | €177k |
| Balance sheet, Equity & liabilities | ||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €1.03M | €872k | €794k |
| Equity | 10/15 | €680k | €736k | €582k |
| Contributions / capital | 10/11 | €19k | €19k | €19k |
| Reserves | 13 | €662k | €718k | €506k |
| Accumulated profits (losses) | 14 | - | - | €58k |
| Provisions & deferred taxes | 16 | €136k | - | - |
| Amounts payable | 17/49 | €211k | €136k | €212k |
| Amounts payable after one year | 17 | €67k | €81k | €95k |
| Amounts payable within one year | 42/48 | €144k | €55k | €117k |
| Trade debts payable within one year | 44 | €386 | €7k | €9k |
| Income statement | ||||
| Gross operating margin | 9900 | €309k | €362k | €228k |
| Operating result | 9901 | €151k | €317k | €201k |
| Financial income | 75 | €3k | €18k | €13k |
| Financial charges | 65 | €2k | €3k | €2k |
| Result before taxes | 9903 | €152k | €331k | €211k |
| Income taxes | 67/77 | €77k | €65k | €37k |
| Net result for the period | 9904 | €75k | €267k | €174k |
| Result to be appropriated | 9905 | €75k | €267k | €174k |
Legal Structure
| NACE primary | Specialist medical practice(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 04-12-2002 |
| Status | Active |
| Postal code | 1160 |
Establishment units
ENDOCRINE UNIT
since 20032.246.929.180
Real-estate footprint
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21332B0494/00W006 | Brussels | 776 m² | 1 · 140 m² | 11.0 m · 3 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2025
15-10
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
31-03
Financial
Weakest financial yearnet €75k ▼71.7%
Net result drops to €75k, the lowest in the series.
2024
25-10
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
31-03
Financial
Highest result since 2023net €267k ▲53%
Operating result €317k, net result €267k, both a record.
31-03
Financial
Liquidity doublescurrent ratio 10.83
Current ratio from 4.48 to 10.83; short-term debt falls from €117k to €55k.
15-01
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 76 days late
2023
05-01
NBB filing
Annual accounts filed
fiscal year 2022 · full schema · 66 days late
04-01
NBB filing
Annual accounts filed
fiscal year 2021 · full schema · 430 days late
2020
29-10
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2019
31-10
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
2018
30-11
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema · 30 days late
2017
30-11
NBB filing
Annual accounts filed
fiscal year 2017 · full schema · 30 days late
2016
30-09
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Specialist medical practice86220
Names & trade names
| Legal nameFR | ENDOCRINE UNIT |
Similar companies
DR BART VISSERS
BE 0478.554.844 · Schoten
Dr. H. Van Kerckhoven - Anesthesie
BE 0518.987.315 · Sint-Niklaas
DR. DE CUYPER EVA
BE 0822.147.452 · Genk
DECLERCQ MD
BE 0521.715.290 · Staden
Dermatoloog Raes
BE 0848.730.105 · Hoogstraten